<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138107</url>
  </required_header>
  <id_info>
    <org_study_id>SYNSS_02</org_study_id>
    <nct_id>NCT05138107</nct_id>
  </id_info>
  <brief_title>Prospective Placebo-controlled Study of Synochi Scar Spray</brief_title>
  <official_title>Prospective Placebo-controlled Study of Synochi Scar Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Synochi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImmunoVation, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Synochi, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo controlled, prospective, split-scar study of severe burn&#xD;
      victims with autologous skin transplants. 9 months intervention time and 3 months follow-up,&#xD;
      photographic scar documentation, self-and observer questionnaires throughout&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, comparative, prospective, evaluator blinded, randomized, placebo- controlled,&#xD;
      split-scar model longitudinal study including 28-31 healthy study participants (See Section 6&#xD;
      Statistical Considerations) with both the original burn scar area that is the skin graft&#xD;
      recipient area and the skin graft donor site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>improvement of cosmetic appearance Synochi Scar Spray versus Placebo</measure>
    <time_frame>12 month study time frame</time_frame>
    <description>Section I of the Patient Scar Assessment Questionnaire (9 questions) minimum 9 points, maximum 36 with higher ratings indicating less improvement of cosmetic appearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the safety of Synochi Scar Spray</measure>
    <time_frame>12 month study time frame</time_frame>
    <description>Safety of Synochi Scar Spray as indicated by absence of adverse events and/or severe adverse events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Burns Multiple</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Synochi Scar Spray Cosmetic</intervention_name>
    <description>Application of the cosmetic and placebo on each skin graft in a blinded fashion in different sections for a 9 month duration.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Study participants are healthy study participants from any sex and race, but must be&#xD;
             between 22 and 50 years of age at the time of consent.&#xD;
&#xD;
          -  Study participants must be willing to provide written informed consent and be able to&#xD;
             read, write, speak, and understand the test procedures in English. Ability will be&#xD;
             documented with a doctors' note.&#xD;
&#xD;
          -  Study participants must be willing to sign a Photo and Video Release Form.&#xD;
&#xD;
          -  Study participants must possess both the original burn scar area that is the skin&#xD;
             graft recipient area and the skin graft donor site that is at least around 6 weeks old&#xD;
             that have not been altered in any way prior (No prior scar reduction surgery, laser,&#xD;
             steroid injections, silicone sheets or anything of the like).&#xD;
&#xD;
          -  Study participants must be in good general health.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Study participants must not currently be under the care of a medical or cosmetic&#xD;
             professional for care of the scar to be evaluated in testing.&#xD;
&#xD;
          -  They must be without medical diagnosis of medicated or uncontrolled diabetes,&#xD;
             hepatitis B, hepatitis C, an organ transplant, a heart murmur, mitral valve prolapse&#xD;
             with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, moderate to&#xD;
             severe asthma (requiring daily use of systemic steroid medication, nasal steroids are&#xD;
             permitted), an immunocompromised condition such as AIDS (or HIV positive), lupus, or&#xD;
             medicated multiple sclerosis, not pregnant or trying to become pregnant, lactating,&#xD;
             transplant recipient on immunosuppression, the BMI should be 19 - &lt; 35.&#xD;
&#xD;
          -  Have any type of vascular disease (e.g., arteriosclerosis, Raynaud's Syndrome, or&#xD;
             peripheral venous disease) or any blood clotting disorders.&#xD;
&#xD;
          -  Have participated in another clinical study within the past 14 days, or be currently&#xD;
             participating in another clinical study.&#xD;
&#xD;
          -  Have or have someone in their household with known sensitivities or allergies to latex&#xD;
             (rubber), bar or liquid cleansing products, serums, moisturizers, lotions, creams,&#xD;
             preservatives, fragrances, cosmetics, or common ingredients used in traditional&#xD;
             Chinese medicine, including Notopterygium root (Notopterygium Incisum), sweetgum fruit&#xD;
             ( Liquidambaris Fructus), bur reed rhizome (Rhizoma Sparganii), corydalis rhizome&#xD;
             (Rhizoma Corydalis), ledebouriella root / siler (Radix Saposhnikoviae), costus root&#xD;
             (Radix Auklandiae Lappae), rehmannia root (Radix Rehmanniae Preparata), deer horn&#xD;
             gelatin/glue (Gelatinum Cornu Cervi), safflower (Carthamus Tinctorius), forsythia&#xD;
             fruit (Fructus Forsythiae), red earthworm (Lumbricus), trichosanthes root (Radix&#xD;
             Trichosanthes), Chinese motherwort (Herba Leonuri), millettia vine (Caulis&#xD;
             Spatholobi), zedoary rhizome (Rhizoma Curcumae), turmeric tuber (Radix Curcumae),&#xD;
             rhubarb (Radix et Rhizoma Rhei), white peony root (Radix Paeoniae Alba), white mustard&#xD;
             seed (Semen Sinapis Albae), Chinese angelica root (Angelicae sinensis Radix), cinnamon&#xD;
             twig (Ramulus Cinnamomi), red peony (Radix Paeoniae Rubra), peach kernel (Semen&#xD;
             Persicae), astragalus (Radix Astragali), frankincense resin (Resina Boswelliae&#xD;
             Carterii), myrrh (Resina Commiphorae Myrrhae), sandalwood (Santalum Album), radiz&#xD;
             notoginseng (Radix Notoginseng), spine of honey locust (Spina Gleditsiae), silkworm&#xD;
             (Bombyx Batryticatus)&#xD;
&#xD;
          -  Have experienced hives (raised welts) as a reaction to anything contacting their skin.&#xD;
&#xD;
          -  Not be diagnosed with a medical condition that, in the opinion of the Principal&#xD;
             Investigator, would preclude participation.&#xD;
&#xD;
          -  Not be unwilling to fulfill the performance requirements of the study.&#xD;
&#xD;
          -  Not be direct employees, in a relationship with, or family of the sponsor or Principal&#xD;
             Investigator.&#xD;
&#xD;
          -  Not be participating in any other clinical trial during the time of this clinical&#xD;
             trial.&#xD;
&#xD;
          -  Medication: Not be receiving any steroid medications (including those used to treat&#xD;
             asthma) other than for contraception, hormone therapy, or menopausal purposes. No&#xD;
             chemotherapeutic agents or any medication that interferes with wound healing&#xD;
             (rheumatologic agents, Emgality or Aimovig).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Jusitn Gillenwater, MD</last_name>
    <phone>(323)409-7750</phone>
    <email>Justin.Gillenwater@med.usc.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autologous skin transplant</keyword>
  <keyword>appearance</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

